Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Jia, JianMin ^a   Xu, XiaoLi ^a   Liu, Fang ^a   Guo, XiaoKe ^a   Zhang, MingYe ^a   Lu, MengChen ^a   Xu, LiLi ^a   Wei, JinLian ^a   Zhu, Jia ^a   Zhang, ShengLie ^a   Zhang, ShengMiao ^a   Sun, HaoPeng ^a   You, QiDong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG IDENTIFICATION; IC 50; PHARMACOPHORE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875672764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059315     Document Type: Article

References (36)

1. Young JC, Agashe VR, Siegers K, Hartl FU, (2004) Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 5: 781-791.
2. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
3. Lisandra MG, Ramos HIC, (2009) Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics. Current Chemical Biology 3: 330-341.
4. Maloney A, Workman P, (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2: 3-24.
5. Pratt WB, Toft DO, (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133.
6. Chiosis G, Vilenchik M, Kim J, Solit D, (2004) Hsp90: the vulnerable chaperone. Drug Discov Today 9: 881-888.
7. Messaoudi S, Peyrat JF, Brion JD, Alami M, (2008) Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 8: 761-782.
8. Pratt WB, Morishima Y, Peng HM, Osawa Y, (2010) Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) 235: 278-289.
9. Isaacs JS, Xu W, Neckers L, (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217.
10. Kamal A, Boehm MF, Burrows FJ, (2004) Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10: 283-290.
11. Shi J, Van de Water R, Hong K, Lamer RB, Weichert KW, et al. (2012) EC144 is a potent inhibitor of the heat shock protein 90. J Med Chem 55: 7786-7795.
12. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
13. Workman P, (2004) Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51.
14. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, et al. (1995) erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 38: 3813-3820.
15. Glaze E, Lambert A, Smith A, Page J, Johnson W, et al. (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemotherapy and Pharmacology 56: 637-647.
16. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, et al. (2006) Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49: 4606-4615.
17. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, et al. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940-7946.
18. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, et al. (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302-8307.
19. Tse AN, Klimstra DS, Gonen M, Shah M, Sheikh T, et al. (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 14: 6704-6711.
20. Taldone T, Gozman A, Maharaj R, Chiosis G, (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8: 370-374.
21. Banerji U, (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15: 9-14.
22. Pearl LH, Prodromou C, Workman P, (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410: 439-453.
23. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, et al. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218.
24. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, et al. (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemotherapy and Pharmacology 55: 21-32.
25. Wang J, Chen L, Sinha SH, Liang Z, Chai H, et al. (2012) Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. J Med Chem 55: 7978-7987.
26. Verheij MH, Thompson AJ, van Muijlwijk-Koezen JE, Lummis SC, Leurs R, et al. (2012) Design, Synthesis, and Structure-Activity Relationships of Highly Potent 5-HT(3) Receptor Ligands. J Med Chem 55: 8603-8614.
27. Huang D, Gu Q, Ge H, Ye J, Salam NK, et al. (2012) On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches. J Chem Inf Model 52: 1356-1366.
28. Chen YD, Jiang YJ, Zhou JW, Yu QS, You QD, (2008) Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 26: 1160-1168.
29. Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, et al. (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 52: 4794-4809.
30. Brough PA, Barril X, Beswick M, Dymock BW, Drysdale MJ, et al. (2005) 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett 15: 5197-5201.
31. Lee HS, Lee CS, Kim JS, Kim DH, Choe H, (2009) Improving virtual screening performance against conformational variations of receptors by shape matching with ligand binding pocket. J Chem Inf Model 49: 2419-2428.
32. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.
33. Harder KW, Owen P, Wong LK, Aebersold R, Clark-Lewis I, et al. (1994) Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides. Biochem J 298 (Pt 2): 395-401.
34. Maehama T, Taylor GS, Slama JT, Dixon JE, (2000) A sensitive assay for phosphoinositide phosphatases. Anal Biochem 279: 248-250.
35. Henkel RD, VandeBerg JL, Walsh RA, (1988) A microassay for ATPase. Anal Biochem 169: 312-318.
36. Massey AJ, (2010) ATPases as Drug Targets: Insights from Heat Shock Proteins 70 and 90. Journal of Medicinal Chemistry 53: 7280-7286.